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TO THE EDITOR:
Cystic fibrosis (CF) pulmonary exacerbations (PEx) 
cause approximately 50% of the decline in lung function. (1) 
Although there is no consensus, the criteria for defining 
PEx currently consist of abnormal sputum and/or chest 
X-ray findings; anorexia; increased cough; dyspnea; 
fatigue/lethargy; fever; hemoptysis; decreased overall 
health status; > 10% decrease in FEV1; and weight loss. 
(2) 
However, two questions remain unanswered(1): how can 
we improve the treatment of PEx and which imaging 
techniques can indicate PEx and/or assess pulmonary 
involvement? Within this context, we can highlight 
the use of lung ultrasound (LUS), which is a rapid, 
radiation-free method that is easily reproducible, widely 
available, and low cost. LUS can be useful for assessing 
PEx and response to antibiotic therapy. Experimentally, 
we used LUS before and after antibiotic therapy in two 
female CF patients who had PEx. The female CF patients 
had two sweat chloride results ≥ 60 mEq/L and two 
pathogenic variants in the CFTR gene. The following 
assessments were performed: completion of a clinical/
demographic questionnaire; spirometry; chest HRCT 
on the day of the first LUS was performed; use of the 
Bhalla CT scoring system; measurement of SpO2; LUS; 
and routine sputum culture (Table 1). This study was 
approved by the local research ethics committee (CAAE 
no. 64515817.4.0000.54.04).
According to the international recommendation for 
point-of-care LUS, this test can detect the presence of 
A-pattern (normal lung sliding and regular pleural line 
echogenicity with a predominance of A-line artifacts) or 
B-pattern (presence of at least three B-line artifacts) 
per lung region.(3,4) In our study, the lung was divided 
into 12 regions. The physical and anatomical nature of 
B-lines (“comet tail” artifacts; hyperechoic, vertical lines 
that mask A-lines originating from the visceral pleura 
and move with lung sliding) is not fully understood; 
however, their occurrence is associated with the presence 
of hydrostatic and/or inflammatory fluid in the lung 
interstitium.(4) In addition, LUS can identify consolidation 
(hypoechoic subpleural area with irregular margins and 
heterogeneous texture, possibly with a hyperechoic image 
inside and/or B-lines adjacent to its posterior margin or 
an aspect similar to that of the liver parenchyma) and 
pleural effusion (anechoic space between the visceral and 
parietal pleura).(3)Patient 1 (CFTR genotype, F508del/
G542X) met the following criteria for PEx: increased 
cough; increased sputum production and change in 
sputum appearance/consistency; worsening of findings on 
pulmonary auscultation; and positive routine culture for 
Staphylococcus aureus and Achromobacter xylosoxidans. 
During follow-up, oral antibiotic therapy was prescribed 
for 15 days. The Shwachman-Kulczycki (SK) score(5) 
indicated lack of resistance and end-of-day tiredness, 
but good school attendance (general activity domain); 
presence of obstructive pulmonary disease, infection, 
lobular atelectasis, and bronchiectasis (radiological 
findings domain); weight and height around the 25th 
percentile, good muscle mass and tone, and well-formed, 
near-normal stools (nutrition domain); and no cough, 
normal heart and respiratory rates, clear lungs, and good 
posture (physical examination domain). In the assessment 
of PEx, we considered the patient’s or caregiver’s report 
of increased cough, increased sputum production, and/
or change in sputum appearance/consistency. However, 
in the SK score,(5) the presence of cough was assessed 
during the visit, and this information was different from 
what was reported previously. In summary, the total 
SK score was 75, classified as “good”. LUS assessment 
showed that, in four lung regions, the pattern changed 
from B to A after antibiotic therapy, being classified as 
a mixed pattern at both time points (Table 1).
Patient 2 (CFTR genotype, F508del/F508del) met the 
following criteria for PEx: increased cough; increased 
sputum production and change in sputum consistency; 
tiredness; intolerance to physical exertion; weigh loss; 
decreased SpO2; and positive routine culture for mucoid 
and nonmucoid Pseudomonas aeruginosa. During 
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follow-up, oral antibiotic therapy was prescribed for 
15 days. The SK score(5) indicated lack of resistance 
and end-of-day tiredness, but good school attendance 
(general activity domain); presence of obstructive 
pulmonary disease, infection, lobular atelectasis, and 
bronchiectasis (radiological findings domain); weight 
and height below the 3rd percentile, weak muscle 
tone, reduced muscle mass, mild/moderate abdominal 
distention, and voluminous, greasy, poorly-formed 
stools (nutrition domain); frequent cough, usually 
productive, chest retraction, moderate emphysema, 
chest deformity, frequent crackles, and digital clubbing 
(physical examination domain). The total SK score was 
45, classified as “moderate”. LUS assessment showed 
that, in one lung region, the pattern changed from B to 
A after antibiotic therapy, being classified as a mixed 
pattern at both time points (Table 1).
Both patients were chronically colonized/infected with 
the aforementioned bacteria and had changes in routine 
culture results from before to after antibiotic therapy.
The LUS images were examined by a pulmonologist 
with specific training in LUS interpretation. A second 
member of the team who specialized in radiology 
analyzed the LUS findings in a blind fashion. Both 
professionals scored the LUS images and interpreted 
the image findings, with identical results. The ultrasound 
scoring system and the full description of the methods 
have been published elsewhere.(6)
In reviewing the literature, there is an evident need 
for a test for assessing antibiotic therapy success in 
PEx. In addition, there is no consensus regarding the 
criteria defining the start/end of PEx and the time 
required for treatment. Furthermore, it is not always 
possible to identify who will require short-course 
antibiotic therapy (10-14 days, early responders) 
or long-course antibiotic therapy (approximately 21 
days, late responders).(1,7) Although clinical markers 
and pulmonary function test results have been 
used as tools to assess response to treatment, they 
have limitations and lose specificity as the disease 
progresses.(1) In this context, our report encourages 
the applicability of LUS for assessing PEx.
In CF, PEx are markers of disease progression 
and should be monitored during routine visits. We 
know that CF patients have experienced an increase 
in survival despite chronic airway colonization with 
Table 1. Data from cystic fibrosis patients and from lung ultrasound assessments before and after antibiotic therapy.
Data Patient 1 Patient 2
Before After Before After
Age, years 22 18
BMI, kg/m2 23.34 17.41
SpO2 95 92
Comorbidities PIns PIns, DM
CFTR F508del/G542X F508del/F508del
FVC, % predicted 73 74 38 39
FEV1, % predicted 55 57 42 41
FEV1/FVC 75 77 99 94
FEF25-75%,% 24 26 53 46
Bhallaa 21 24
Regions assessed on LUS
1 A A B A + PI
2 C + PI C + PI B + C B + C
3 B A B B
4 B + PI B + PI B B
5 A + PI A B B
6 B A B + C B + C
7 A A B B
8 B B B B
9 A + PI A B + C B + C
10 B A B + PI B + PI
11 A A B B
12 B A B B
Scoreb 8/36 4/36 18/36 17/36
BMI: body mass index; PIns: pancreatic insufficiency; DM: diabetes mellitus; CFTR: cystic fibrosis transmembrane 
regulator; LUS: lung ultrasound; A: A-pattern; B: B-pattern; PI: pleural irregularity; and C: consolidation. aThe 
modified Bhalla CT scoring system was used as in Folescu et al.(10): the total score for each patient is obtained by 
summing the scores for each morphological change, which are attributed on the basis of the severity/extent of the 
abnormality. The total score can range from zero (absence of abnormalities) to 37 (all abnormalities present and 
severe). bThe higher the proportion value, the greater the pulmonary involvement in the area, with the presence 
of consolidation being assigned 2 points and the presence of B-pattern being assigned 1 point. Therefore, the 
maximum score is 36 points.
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bacteria exhibiting increased drug resistance, which 
culminates in the use of numerous drugs (antibiotics 
and anti-inflammatory drugs) that require frequent 
monitoring, since we move toward personalized and 
precision medicine.(8,9) In this process, LUS could 
be a tool that accompanies patients in determining 
their individual response to therapy, without causing 
complications or exposing patients to radiation.
In summary, LUS could be a useful tool to assess 
changes due to PEx and response to antibiotic therapy 
in CF. However, further studies involving a larger sample 
size are needed in order to confirm our findings, since 
only one of the two CF patients assessed had distinctly 
different LUS results before and after antibiotic therapy.
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